SimpleFunctions
Winner-take-all answer·5 source contracts·Kalshi 5·refreshed just now·Closes Jan 1, 2029 · 864d

When will the FDA approve retatrutide (LY3437943)

Leader sits at 91% across 5 bound outcomes, runner-up at 87%. This is a winner-take-all market — the headline is the leader’s price, not an arithmetic mean.

Leader probability

91%

Before Jan 1, 2029

runner-up 87¢leader 91¢

Outcomes

5

winner-take-all

Runner-up

87¢

Before Jul 1, 2028

Spread

4pp

contested

24h volume

$245

thin orderbook

Closes

Jan 1, 2029

864 days

Venue

Kalshi

5 bound

30-day trend

0%50%100%-30d-3w-2w-1wtodayBefore Jan 1, 2029: 91% (27 days, 25 points)Before Jan 1, 2029: 91% on 2026-08-21Before Jul 1, 2028: 87% (27 days, 25 points)Before Jul 1, 2028: 87% on 2026-08-21Before Jan 1, 2028: 80% (27 days, 24 points)Before Jan 1, 2028: 80% on 2026-08-21
Before Jan 1, 202991¢Before Jul 1, 202887¢Before Jan 1, 202880¢
Top 3 candidates by current price · 27d

Bracket family

How the bracket ladder is priced.

Each row is one outcome on the venue. Sorted by 24h volume — the heaviest book is at the top.

Analysis

Markets currently assign a 92% probability that the FDA will approve retatrutide (Eli Lilly's obesity and diabetes drug) by January 1, 2029. This reflects confidence in eventual approval, though the contract chain shows material uncertainty about timing—traders see only a 16% chance of approval before January 2027, suggesting the review process extends beyond near-term. The probability is elevated by retatrutide's clinical trial data and Lilly's development track record with similar GLP-1 compounds, but remains below certainty because regulatory outcomes are never guaranteed. FDA action timelines depend on submission completeness, any safety signals during review, and the agency's current workload. The most immediate resolution point would be a formal FDA decision or any major clinical or manufacturing disclosure that affects approval likelihood.

  • Retatrutide has shown clinical efficacy in Phase 3 trials, but approval hinges on FDA's safety and manufacturing review standards, which can extend timelines unpredictably
  • The 65-cent contract for approval by July 2027 suggests a base-case timeline of 12–18 months from now, implying submission may already be in progress or imminent
  • No scheduled FDA decision date is publicly confirmed; a breakthrough designation or priority review status would accelerate approval odds materially
  • Manufacturing scale-up or supply-chain constraints could delay launch even after regulatory clearance
  • Competitive GLP-1 drug approvals and label expansions may influence FDA prioritization but do not directly determine retatrutide's path

What moved the line

  • Aug 19Before Jul 1, 202823pp8764¢ · Kalshi
  • Aug 19Before Jan 1, 202923pp9168¢ · Kalshi
  • Aug 20Before Jul 1, 202816pp6480¢ · Kalshi
  • Aug 20Before Jan 1, 202915pp6883¢ · Kalshi
  • Aug 14Before Jul 1, 202810pp8878¢ · Kalshi

Recently closed in general

These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.

More like this

Adjacent prediction questions.

How we compute these odds

SimpleFunctions aggregates live prediction-market contracts from Kalshi and Polymarket. Each slug groups contracts that resolve on the same underlying event, identified by venue event_id.

For binary slugs, the headline probability is the liquidity-weighted mid-price across all bound contracts. For multi-outcome slugs (e.g. elections with 3+ candidates), the headline is the leader’s price; we never arithmetically average disjoint outcomes — that would produce a number with no real-world meaning.

Snapshots refresh every 5 minutes during market hours; daily aggregates are computed at 04:00 UTC. The 30-day sparkline is drawn from per-ticker daily means stored in market_indicator_daily; 24h delta and movement events are derived from the same source.

Last updated on this page: just now.